Canada Gazette, Part I, Volume 157, Number 12: GOVERNMENT NOTICES

March 25, 2023

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Draft Federal Environmental Quality Guidelines for triclocarban

Whereas the Minister of the Environment issues environmental quality guidelines for the purpose of carrying out the Minister’s mandate related to preserving the quality of the environment;

Whereas the guidelines relate to the environment pursuant to paragraph 54(2)(a) of the Canadian Environmental Protection Act, 1999;

And whereas the Minister of the Environment has offered to consult provincial and territorial governments, and the members of the National Advisory Committee who are representatives of Indigenous governments in accordance with subsection 54(3) of the Act,

Notice is hereby given that the draft Federal Environmental Quality Guidelines for triclocarban are available on the Canada.ca (Chemical substances) website.

Public comment period

Any person may, within 60 days after publication of this notice, file with the Minister of the Environment written comments on the scientific considerations on the basis of which the guidelines are made. More information regarding the scientific considerations may be obtained from the Canada.ca (Chemical substances) website. All comments must cite the Canada Gazette, Part I, and the date of publication of this notice and be addressed to the Executive Director, Program Development and Engagement Division, Department of the Environment, Gatineau, Quebec K1A 0H3, by email to substances@ec.gc.ca or by using the online reporting system available through Environment and Climate Change Canada’s Single Window.

Jacqueline Gonçalves
Director General
Science and Risk Assessment Directorate
On behalf of the Minister of the Environment

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Order 2023-87-04-02 Amending the Non-domestic Substances List

Whereas, under subsection 87(5) of the Canadian Environmental Protection Act, 1999 footnote a, the Minister of the Environment has added the substance referred to in the annexed Order to the Domestic Substances List footnote b;

Therefore, the Minister of the Environment makes the annexed Order 2023-87-04-02 Amending the Non-domestic Substances List under subsection 87(5) of the Canadian Environmental Protection Act, 1999 footnote a.

Gatineau, March 13, 2023

Steven Guilbeault
Minister of the Environment

Order 2023-87-04-02 Amending the Non-domestic Substances List

Amendment

1 Part I of the Non-domestic Substances List footnote 1 is amended by deleting the following:

Coming into Force

2 This Order comes into force on the day on which Order 2023-87-04-01 Amending the Domestic Substances List comes into force.

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Waiver of information requirements for living organisms (subsection 106(9) of the Canadian Environmental Protection Act, 1999)

Whereas any person who proposes to import or manufacture a living organism that is not on the Domestic Substances List must provide to the Minister of the Environment the information required under subsection 106(1) of the Canadian Environmental Protection Act, 1999; and

Whereas a person may, pursuant to subsection 106(8) of the Canadian Environmental Protection Act, 1999, request that any of the requirements to provide information under subsection 106(1) of the Canadian Environmental Protection Act, 1999 be waived.

Therefore, notice is hereby given, pursuant to subsection 106(9) of the Canadian Environmental Protection Act, 1999, that the Minister of the Environment waived some requirements to provide information in accordance with the following annex pursuant to subsection 106(8) of that Act.

Thomas Kruidenier
Acting Executive Director
Program Development and Engagement Division
On behalf of the Minister of the Environment

ANNEX

Waiver of information requirements

(Subsection 106(9) of the Canadian Environmental Protection Act, 1999)
Person to whom a waiver was granted Information concerning a living organism in relation to which a waiver was granted
Neuracle Genetics Inc.
  • Data from tests to determine the effects of the living organism on aquatic plant, invertebrate, and vertebrate species likely to be exposed
  • Data from tests to determine the effects of the living organism on terrestrial plant, invertebrate, and vertebrate species likely to be exposed
  • Data from tests of antibiotic susceptibility
Novozymes Canada Limited Data from tests to determine the effects of the living organism on aquatic plant, invertebrate, and vertebrate species likely to be exposed
Syneos Health
  • Data from tests to determine the effects of the living organism on aquatic plant, invertebrate, and vertebrate species likely to be exposed
  • Data from tests to determine the effects of the living organism on terrestrial plant, invertebrate, and vertebrate species likely to be exposed
  • Data from tests of antibiotic susceptibility
Synlogic Operating Company Inc.
  • Data from tests to determine the effects of the living organism on aquatic plant, invertebrate, and vertebrate species likely to be exposed
  • Data from tests to determine the effects of the living organism on terrestrial plant, invertebrate, and vertebrate species likely to be exposed

EXPLANATORY NOTE

The decision to grant a waiver is made on a case-by-case basis by the Minister of the Environment in consultation with the Minister of Health. Every year, an average of approximately 400 regulatory declarations are submitted for chemicals, polymers and living organisms under subsections 81(1), (3) and (4) and 106(1), (3) and (4) of the Canadian Environmental Protection Act, 1999 and around 100 waivers are granted yearly for chemicals, polymers and living organisms under subsections 81(8) and 106(8) of the Canadian Environmental Protection Act, 1999.

For more information, please see the waivers web page on the New Substances website.

DEPARTMENT OF THE ENVIRONMENT

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Waiver of information requirements for substances (subsection 81(9) of the Canadian Environmental Protection Act, 1999)

Whereas any person who proposes to import or manufacture a substance that is not on the Domestic Substances List must provide to the Minister of the Environment the information required under subsection 81(1) of the Canadian Environmental Protection Act, 1999; and

Whereas a person may, pursuant to subsection 81(8) of the Canadian Environmental Protection Act, 1999, request any of the requirements to provide information under subsection 81(1) of the Canadian Environmental Protection Act, 1999 to be waived;

Therefore, notice is hereby given, pursuant to subsection 81(9) of the Canadian Environmental Protection Act, 1999, that the Minister of the Environment waived some requirements to provide information pursuant to subsection 81(8) of that Act and in accordance with the following annex.

Thomas Kruidenier
Acting Executive Director
Program Development and Engagement Division
On behalf of the Minister of the Environment

ANNEX

Waiver of information requirements

(Subsection 81(9) of the Canadian Environmental Protection Act, 1999)
Person to whom a waiver was granted Information concerning a substance in relation to which a waiver was granted
BASF Canada Inc.
  • Data in respect of vapour pressure
  • Data in respect of hydrolysis rate as a function of pH
  • Data from an in vivo mammalian mutagenicity test for chromosomal aberrations or gene mutations
Genomatica Inc.
  • Data in respect of density
  • Data in respect of hydrolysis rate as a function of pH
IGM Resins USA Inc.
  • Data in respect of boiling point
  • Data in respect of hydrolysis rate as a function of pH
Origin Materials Canada Polyesters Limited
  • Data from an in vivo mammalian mutagenicity test for chromosomal aberrations or gene mutations
  • Data from an acute fish, daphnia or algae toxicity test
Sherwin-Williams Canada Inc.
  • Data in respect of hydrolysis rate as a function of pH
  • Data from an in vivo mammalian mutagenicity test for chromosomal aberrations or gene mutations
Solvay Canada Inc.
  • Data from an adsorption-desorption screening test
  • Data in respect of hydrolysis rate as a function of pH

EXPLANATORY NOTE

The decision to grant a waiver is made on a case-by-case basis by the Minister of the Environment in consultation with the Minister of Health. Every year, an average of approximately 400 regulatory declarations are submitted for chemicals, polymers and living organisms under subsections 81(1), (3) and (4) and 106(1), (3) and (4) of the Canadian Environmental Protection Act, 1999, and around 100 waivers are granted yearly for chemicals, polymers and living organisms under subsections 81(8) and 106(8) of the Canadian Environmental Protection Act, 1999.

For more information, please see the waivers web page on the New Substances website.

DEPARTMENT OF THE ENVIRONMENT DEPARTMENT OF HEALTH

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Publication of final decision after screening assessment of a substance — urea, N-(4-chlorophenyl)-N′-(3,4-dichlorophenyl)- (triclocarban), CAS RN footnote 1 101-20-2 — specified on the Domestic Substances List (subsection 77(6) of the Canadian Environmental Protection Act, 1999)

Whereas triclocarban is a substance identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999;footnote 2

Whereas a summary of the screening assessment conducted on triclocarban pursuant to section 74 of the Act is annexed hereby;

And whereas it is concluded that the substance does not meet any of the criteria set out in section 64 of the Act,

Notice therefore is hereby given that the Minister of the Environment and the Minister of Health (the ministers) propose to take no further action on this substance at this time under section 77 of the Act.

Notice is hereby further given that options are being considered for follow-up activities to track changes in exposure to triclocarban.

Steven Guilbeault
Minister of the Environment

Jean-Yves Duclos
Minister of Health

ANNEX
Summary of the screening assessment of triclocarban

Pursuant to section 74 of the Canadian Environmental Protection Act, 1999 (CEPA), the Minister of the Environment and the Minister of Health (the ministers) have conducted a screening assessment of urea, N-(4-chlorophenyl)-N′-(3,4-dichlorophenyl)-, hereinafter referred to as triclocarban. The Chemical Abstracts Service Registry Number (CAS RN) for triclocarban is 101-20-2.

According to information submitted in response to CEPA section 71 surveys, triclocarban was reported to be imported into Canada in volumes in the range of 10 000 kg to 100 000 kg and 1 000 kg to 10 000 kg in 2008 and 2015, respectively, but was not reported to be manufactured in Canada above the reporting threshold of 100 kg. Triclocarban is used in Canada in products available to consumers, including in a limited number of cosmetics such as bar soaps and facial cleansers.

The ecological risk of triclocarban was characterized using the ecological risk classification of organic substances (ERC), which is a risk-based approach that employs multiple metrics for both hazard and exposure, with weighted consideration of multiple lines of evidence for determining risk classification. Hazard profiles are based principally on metrics regarding mode of toxic action, chemical reactivity, food web–derived internal toxicity thresholds, bioavailability, and chemical and biological activity. Metrics considered in the exposure profiles include potential emission rate, overall persistence, and long-range transport potential. A risk matrix is used to assign a low, moderate or high level of potential concern for substances on the basis of their hazard and exposure profiles. The ERC approach resulted in an exposure classification of low for triclocarban, based on its reported use patterns, and in a hazard classification of moderate. As this substance is known to possess antibacterial properties, its hazard classification was reviewed using a broader set of data than considered under the initial ERC analysis. Based on this additional analysis, triclocarban is considered to have a high hazard based on its inherent toxicity in aquatic organisms and high potential for bioaccumulation in aquatic invertebrates. However, due to its limited exposure potential, triclocarban is considered unlikely to be causing ecological harm.

Considering all available lines of evidence presented in this screening assessment, there is a low risk of harm to the environment from triclocarban. It is concluded that triclocarban does not meet the criteria under paragraph 64(a) or (b) of CEPA, as it is not entering the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.

The critical health effect identified for triclocarban was reduced absolute and relative organ weights (spleen, kidneys, liver, adrenal, heart, and pituitary) with changes in organ histology in animal studies. Triclocarban exposure also produced effects on fecal microbial diversity, body weight and organ weight in repeated-dose studies. Effects on male reproductive tissues, reproduction, live births, reduced rat pup body weight and reduced pup survival were observed in animal studies. Canadians are mainly exposed to triclocarban via the use of cosmetics as well as from food and the environment (drinking water, soil, and house dust). Canadian biomonitoring data indicated that the majority of the population has a low exposure to triclocarban. Margins of exposure were considered adequate to address uncertainties in the health effects and exposure databases.

Considering all the information presented in this screening assessment, it is concluded that triclocarban does not meet the criteria under paragraph 64(c) of CEPA, as it is not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.

Overall conclusion

It is therefore concluded that triclocarban does not meet any of the criteria set out in section 64 of CEPA.

Consideration for follow-up

While exposure of the environment to triclocarban is not of concern at current levels, this substance is associated with effects of concern. Therefore, there may be concern if exposure levels were to increase. Follow-up activities to track changes in exposure or commercial use patterns are under consideration, which may include periodic environmental monitoring in surface water and sediment. The Government of Canada has also published federal environmental quality guidelines (FEQGs) for triclocarban in water and sediment. The government will use the data gathered through these follow-up activities to prioritize further information gathering or risk assessment of this substance, if required.

The screening assessment for this substance is available on the Canada.ca (Chemical substances) website.

DEPARTMENT OF HEALTH

CANNABIS ACT

Notice of Intent — Consultation on potential amendments to the Cannabis Regulations

Purpose of notice

This Notice of Intent is to inform Canadians and interested parties that Health Canada is seeking feedback on potential amendments to the Cannabis Regulations (CR) for regulatory burden reduction while still addressing public health and public safety risks. It also provides stakeholders with an opportunity to identify and comment on additional regulatory issues.

Background

The Cannabis Act (the Act) created a legal framework for the production, distribution, sale, import, export, and possession of cannabis in Canada based on a public health and public safety approach. Key public health and public safety objectives include protecting the health of young persons by restricting their access to cannabis, establishing a diverse and competitive market with small and large-scale cannabis producers that can displace the illicit market, and providing adults access to a quality-controlled supply of cannabis.

To help achieve these objectives, Health Canada strictly regulates activities involving cannabis. Regulatory measures in the CR include

A number of policy principles guided the development of the regulatory framework for cannabis. This included risk- and evidence-based requirements informed by the best available science on potential harms and risks posed by cannabis, providing for a broad range of cannabis products to help displace the illicit market, and implementing experiences and lessons learned from other jurisdictions that legalized and regulated cannabis. It also included building on long-standing regulatory frameworks, including industrial hemp, tobacco, food, and cosmetics.

Since the coming into force of the Act and the CR in 2018, the legal cannabis industry has matured, the marketplace has evolved, and there is increased knowledge and data on public health and public safety risks associated with certain activities. Based on the implementation experience gained since the coming into force of the Act, and in keeping with the original policy principles, Health Canada recognizes there may be regulatory measures that could be made more efficient and streamlined without compromising the public health and public safety objectives in the Act.

The proposal

Health Canada is considering potential amendments to the CR that would (1) streamline and clarify existing requirements; (2) eliminate inefficiencies in the regulations, such as duplications between requirements; and (3) reduce administrative and regulatory burdens where possible, while continuing to meet the public health and public safety objectives in the Act.

Regulatory amendments would target the following five priority areas:

  1. Licensing;
  2. Personnel and physical security measures;
  3. Production requirements for cannabis products;
  4. Packaging and labelling requirements for cannabis products; and
  5. Record keeping and reporting for cannabis licence holders.

This proposal is separate and distinct from the Government of Canada’s legislative review of the Cannabis Act, the objective of which is to review the administration and operation of the Act with a focus on young persons, Indigenous persons and communities, personal cultivation; along with reviewing access to cannabis for medical purposes.

Questions to guide input from interested parties

Health Canada is particularly interested in receiving feedback on the five priority areas listed above. However, all input is welcome and should not be limited to responses to the questions posed below. Health Canada is also interested in feedback on regulatory measures that may be duplicative, redundant, or particularly onerous, and where there are opportunities to promote efficiencies. Please provide a rationale and/or evidence wherever possible, including the expected impact on the legal cannabis industry, consumers, and public health and public safety. These responses will help inform and prioritize items for regulatory development and will be reviewed carefully by Health Canada.

1. Licensing

Under the Act, a person is required to obtain a licence to conduct various activities with cannabis. The CR sets out rules and requirements that apply to each licence class (e.g. cultivation, processing, sale) and subclass (e.g. standard and micro). The licensing framework provides for the legal production of cannabis while mitigating public health and public safety risks and reducing the risk of cannabis being diverted to an illicit market.

Some licence holders have raised concerns that some licensing requirements may not be necessary or could be streamlined. Health Canada is considering changes to licensing requirements that would not compromise public health or public safety.

  1. Are there any activities with cannabis that are not currently authorized under existing licences that could be authorized? What specific activities, for which classes of cannabis, and for what classes and subclasses of licences? How would such changes streamline the regulations or lead to greater efficiencies?
  2. Are there any activities with cannabis that organizations should be able to carry out, without the need to hold a licence or permit (for example, the possession of small amounts of licit cannabis for the purpose of laboratory research)? What specific activities and for what classes of cannabis? What measures, including regulatory requirements, should apply to mitigate public health and public safety risks?
  3. What measures could be taken to increase flexibility for licensed cannabis processors and to reduce the burden on the Quality Assurance Person (QAP)?

2. Personnel and physical security measures

A licence holder must comply with the personnel and physical security requirements specific to their licence as per parts 3 and 4 of the CR. These requirements include having a head of security, an organizational security plan, and physical security measures, such as visual recording devices. The personnel and physical security requirements aim to mitigate public health and public safety risks and reduce the risk of cannabis being diverted to an illicit market, among others.

Health Canada has received feedback that certain personnel and physical security requirements may not be necessary or could be streamlined. Health Canada is considering changes to the personal and physical security measures without unduly increasing risks to public health or public safety.

3. Production requirements for cannabis products

Under Part 6 of the CR, there are regulatory requirements related to the formulation, production, and composition of cannabis products. These requirements include, but are not limited to, microbial and chemical contamination limits and prohibited ingredients. These requirements aim to reduce the appeal of cannabis products to young persons; reduce the risk of accidental consumption; mitigate the consequences of overconsumption; reduce the risk of foodborne illness; and reduce the potential for toxicity, dependence or other harmful or unintended responses to cannabis products (i.e. adverse reactions).

Health Canada has heard that there are product requirements that are more burdensome than those in analogous frameworks, such as those for medical devices or cosmetics. Health Canada is considering regulatory changes for some product requirements that would remove unnecessary burden while still supporting the public health and public safety objectives of the Act.

  1. Are there any changes to the current production requirements that could create efficiencies for holders of a micro-cultivation or micro-processing licence?
  2. Are there regulatory requirements from other relevant control frameworks, such as those for food, vaping products, or cosmetics, that Health Canada should consider? Why or why not? For which classes of cannabis?
  3. Are there certain production requirements that could be changed or eliminated for licensed processors that are limited in what activities with cannabis they are authorized to undertake (for example only authorized to store cannabis products)? Which requirements, and under what circumstances?
  4. Should the limits on the maximum quantity of delta-9-THC that can be contained in a cannabis product (by container and ingestible unit) apply to the sum total of all intoxicating cannabinoids found in the product? Why or why not? How could such a requirement be established in an efficient manner that is simple to comply with?

4. Packaging and labelling requirements for cannabis products

The CR sets out requirements for the packaging and labelling of cannabis and cannabis products for sale, distribution, or export. These requirements include plain packaging and labelling for all cannabis products to make packages less appealing to young persons. All cannabis products must also be packaged in a child-resistant container and when the product contains delta-9-THC, it must be labelled with the standardized cannabis (THC) symbol to lower the risk of accidental consumption. In addition, cannabis products must display a mandatory health warning message and include specific product information (e.g. class of cannabis, delta-9-THC and cannabidiol [CBD] information) to provide consumers with the information they need to make informed decisions before using cannabis.

Health Canada has received stakeholder feedback that some packaging and labelling requirements are onerous or unnecessary to achieve the Act’s public health and public safety objectives. Health Canada is considering what packaging and labelling requirements could be changed without compromising these objectives.

  1. Should Health Canada consider amending packaging requirements for dried and fresh cannabis?
  2. Are there labelling requirements that could be changed without public health or public safety impacts? What required information should remain, and what information could be removed? Why or why not?
  3. Do you have any suggestions to simplify the requirements to include delta-9-THC and CBD content information on product labels?
  4. Should the requirement to include delta-9-THC content information on product labels apply to the total of all intoxicating cannabinoids, such as delta-8-THC? Why or why not? How could such a requirement be established in an efficient manner that is simple to comply with?
  5. Are there other packaging and labelling requirements that Health Canada should consider for a regulatory amendment? Why and what is the current impact of these requirements on licence holders and consumers?

5. Record keeping and reporting for cannabis licence holders

The CR establish requirements for federal licence holders respecting the retention of documents and reporting of certain information to Health Canada. Requirements include establishing and maintaining up-to-date inventories and retaining documents such as those related to the production of cannabis products, GPP, packaging and labelling, investors, and notices of new cannabis products to be sold in Canada for the first time. These record-keeping and reporting requirements aid Health Canada in the retrieval of important information to verify regulatory compliance, support operational and policy development, and reduce the risk of inversion and diversion to the illicit market.

Some licence holders have raised concerns with respect to onerous and duplicative requirements. Health Canada is considering regulatory changes that would aim to eliminate duplication between requirements where possible, remove requirements that are not effective in supporting public health and public safety objectives in the Act, and simplify the reporting process.

  1. Are there record-keeping or reporting requirements for micro-class licence holders that could be reduced without affecting public health and public safety? If so, which requirements and why? What is the current impact of these requirements on micro-class licence holders?
  2. Should Health Canada remove the requirement to provide a promotion expenditure report to Health Canada? Why or why not?
  3. Should Health Canada remove the requirement to maintain a record of key investors? Why or why not?
  4. Do you have any suggestions to improve the efficiency of the requirement for licensed processors to provide Health Canada with advance notice of a new cannabis product?
  5. Are there other requirements that could be adjusted for record keeping and reporting?

Next steps

Health Canada will review and consider the input received following publication of this Notice of Intent to inform next steps, including a cost-benefit analysis of the regulatory proposal. Any future regulatory proposal would be prepublished in the Canada Gazette, Part I, for further stakeholder consultation in accordance with the Treasury Board of Canada Secretariat’s Cabinet Directive on Regulation before it is made final.

Public comments

The publication of this Notice of Intent initiates a 60-day public comment period. Health Canada is seeking feedback and comments on potential amendments to the CR. Input received will ensure that regulatory amendments are informed by and responsive to the cannabis industry, other interested parties, and the public. Health Canada welcomes input for 60 calendar days until May 24, 2023.

Contact information

Please submit your input by email to cannabis.consultation@canada.ca with the following title in the subject line: “Notice of Intent — Consultation on Potential Amendments to the Cannabis Regulations”.

John Clare
Director General
Strategic Policy, Cannabis
Controlled Substances and Cannabis Branch

DEPARTMENT OF INDUSTRY

OFFICE OF THE REGISTRAR GENERAL

Appointments

March 17, 2023

Rachida Lagmiri
Official Documents Registrar

DEPARTMENT OF PUBLIC SAFETY AND EMERGENCY PREPAREDNESS

CRIMINAL CODE

Designation as fingerprint examiner

Pursuant to subsection 667(5) of the Criminal Code, I hereby designate the following persons of the Royal Canadian Mounted Police as “fingerprint examiners”:

Ottawa, March 1, 2023

Julie Thompson
Director General
Crime Prevention Branch

DEPARTMENT OF TRANSPORT

AERONAUTICS ACT

Interim Order Respecting Certain Requirements for Civil Aviation Due to COVID-19, No. 79

Whereas the annexed Interim Order Respecting Certain Requirements for Civil Aviation Due to COVID-19, No. 79 is required to deal with a significant risk, direct or indirect, to aviation safety or the safety of the public;

Whereas the provisions of the annexed Order may be contained in a regulation made under sections 4.71footnote c and 4.9footnote d, paragraphs 7.6(1)(a)footnote e and (b)footnote f and section 7.7footnote g of the Aeronautics Act footnote h;

Whereas, under subsection 6.41(1.1)footnote i of the Aeronautics Act footnote h, the Minister of Transport authorized the Deputy Minister of Transport to make an interim order that contains any provision that may be contained in a regulation made under Part I of that Act to deal with a significant risk, direct or indirect, to aviation safety or the safety of the public;

And whereas, in accordance with subsection 6.41(1.2)footnote i of that Act, the Minister of Transport has consulted with the persons and organizations that the Minister considers appropriate in the circumstances before making the annexed Order;

Therefore, the Deputy Minister of Transport makes the annexed Interim Order Respecting Certain Requirements for Civil Aviation Due to COVID-19, No. 79 under subsection 6.41(1.1)footnote i of the Aeronautics Act footnote h.

Ottawa, March 8, 2023

Arun Thangaraj
Deputy Minister of Transport

Interim Order Respecting Certain Requirements for Civil Aviation Due to COVID-19, No. 79

Interpretation

Definitions

1 (1) The following definitions apply in this Interim Order.

air carrier
means any person who operates a commercial air service under Subpart 1, 3, 4 or 5 of Part VII of the Regulations. (transporteur aérien)
COVID-19
means the COVID-19 coronavirus disease. (COVID-19)
COVID-19 antigen test
means a COVID-19 screening or diagnostic immunoassay that
  • (a) detects the presence of a viral antigen indicating the presence of COVID-19;
  • (b) is authorized for sale or distribution in Canada or in the jurisdiction in which it was obtained;
  • (c) if the test is self-administered, is observed and produces a result that is verified
    • (i) in person by an accredited laboratory or testing provider, or
    • (ii) in real time by remote audiovisual means by the accredited laboratory or testing provider that provided the test; and
  • (d) if the test is not self-administered, is performed by an accredited laboratory or testing provider. (test antigénique de la COVID-19)
COVID-19 molecular test
means a COVID-19 screening or diagnostic test, including a test performed using the method of polymerase chain reaction (PCR) or reverse transcription loop-mediated isothermal amplification (RT-LAMP), that
  • (a) if the test is self-administered, is observed and produces a result that is verified
    • (i) in person by an accredited laboratory or testing provider, or
    • (ii) in real time by remote audiovisual means by the accredited laboratory or testing provider that provided the test; or
  • (b) if the test is not self-administered, is performed by an accredited laboratory or testing provider. (test moléculaire de la COVID-19)
COVID-19 test
means either
  • (a) a COVID-19 molecular test, or
  • (b) a COVID-19 antigen test. (test relatif à la COVID-19)
Regulations
means the Canadian Aviation Regulations. (Règlement)
testing provider
means
  • (a) a person who may provide COVID-19 screening or diagnostic testing services under the laws of the jurisdiction where the service is provided; or
  • (b) an organization, such as a telehealth service provider or pharmacy, that may provide COVID-19 screening or diagnostic testing services under the laws of the jurisdiction where the service is provided and that employs or contracts with a person referred to in paragraph (a). (fournisseur de services de tests)

Interpretation

(2) Unless the context requires otherwise, all other words and expressions used in this Interim Order have the same meaning as in the Regulations.

Conflict

(3) In the event of a conflict between this Interim Order and the Regulations or the Canadian Aviation Security Regulations, 2012, the Interim Order prevails.

COVID-19 Tests

Application

2 This Interim Order applies to a private operator or air carrier operating a flight referred to in subsection 2(1) of the Minimizing the Risk of Exposure to COVID-19 in Canada Order.

Prohibition

3 (1) A private operator or air carrier must not permit a person to board an aircraft for a flight that they operate if the person does not provide evidence that they received

Exception

(2) However, a person listed in any of paragraphs 2(2)(a) to (g) of the Minimizing the Risk of Exposure to COVID-19 in Canada Order is not required to provide the evidence referred to in subsection (1).

Evidence of COVID-19 test

4 Evidence of a result for a COVID-19 test must include

Designated Provision

Designation

5 (1) The provision of this Interim Order set out in column 1 of the schedule is designated as a provision the contravention of which may be dealt with under and in accordance with the procedure set out in sections 7.7 to 8.2 of the Act.

Maximum amounts

(2) The amounts set out in column 2 of the schedule are the maximum amounts of the penalty payable in respect of a contravention of the designated provision set out in column 1.

Notice

(3) A notice referred to in subsection 7.7(1) of the Act must be in writing and must specify

Repeal

6 The Interim Order Respecting Certain Requirements for Civil Aviation Due to COVID-19, No. 78, made on February 23, 2023, is repealed.

SCHEDULE

(Subsections 5(1) and (2))

Designated Provision

Column 1

Designated Provision

Column 2

Maximum Amount of Penalty ($)
Individual Corporation
Subsection 3(1) 5,000 25,000

DEPARTMENT OF TRANSPORT

CANADA TRANSPORTATION ACT

Levy on shipments of crude oil by rail

Pursuant to subsection 155.4(4)footnote j of the Canada Transportation Act (the Act), the amount of the levy in respect of payments into the Fund for Railway Accidents Involving Designated Goods required by subsection 155.7(1)footnote c of the Act is $1.99 per tonne during the year commencing April 1, 2023.

March 10, 2023

Omar Alghabra, P.C., M.P.
Minister of Transport

GLOBAL AFFAIRS CANADA

Consulting Canadians on the Americas Partnership for Economic Prosperity

The Government of Canada is committed to diversifying its trade and investment ties with key markets and to promoting shared prosperity through enhanced economic opportunities, governance reforms, and sustainable, inclusive growth, especially in the Americas. This effort includes strengthening the rules-based international trading system, and pursuing inclusive trade. The Government of Canada is soliciting the views of Canadians on the Americas Partnership for Economic Prosperity (APEP).

As steps are taken to ensure Canada advances its commitment to a progressive trade agenda, takes action consistent with Canada’s Feminist International Assistance Policy and promotes an open, inclusive and rules-based system across the region, groups traditionally under-represented such as women, small and medium-sized enterprises (SMEs), Indigenous Peoples, persons with disabilities, youth, 2SLGBTQI+, and racialized communities are especially encouraged to give their input.

Background

Canada’s engagement in the Americas

Canada values the deep, long-standing relationship that it has with the countries and peoples of the Americas. Canada shares geographies, languages, history, culture and familial ties with them, in addition to strong economic relations.

Canada enjoys strong engagement supported by growing trade and investment ties in the Americas region. Canada’s bilateral merchandise trade with APEP members (including the United States) totalled $1.0 trillion in 2022. Canada is a founding member of the Caribbean Development Bank, holds membership in the Organization of American States, the Inter-American Development Bank, the Pan-American Health Organization, and was the first non-Latin country and observer to sign a joint declaration of partnership with the Pacific Alliance. The total value of Canadian international assistance in Latin America and the Caribbean was $1.23 billion in 2020–2021.

Canadians enjoy preferential market access with certain APEP participants through the Canada-United States-Mexico Agreement (CUSMA), the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), and bilateral FTAs with Chile, Colombia, Costa Rica, Honduras, Panama and Peru. To deepen Canada’s economic ties and secure even more opportunities for Canadians in the hemisphere, FTA negotiations are also underway with the Mercosur bloc, and Canada is seeking accession to the Digital Economic Partnership Agreement (DEPA). On November 24, 2022, Canada also launched exploratory discussions towards a potential bilateral FTA with Ecuador.

APEP negotiations

Building on those strong foundations, Minister of International Trade, Export Promotion, Small Businesses and Economic Development Mary Ng joined U.S. Secretary of State Antony Blinken and U.S. Trade Representative Katherine Tai on January 27, 2023, for the launch of APEP along with representatives from 10 countries from the Western Hemisphere that were invited to be founding partners. Those countries are Barbados, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, Mexico, Panama, Peru, and Uruguay. In total, APEP countries represent about 90% of the Western Hemisphere’s GDP and nearly two thirds of its people.

APEP is a flexible framework, open to all countries with common values and a shared vision for a prosperous hemisphere. APEP negotiations will not establish a free trade agreement and is not expected to include tariff reductions or broad market access commitments. Nevertheless, a fully realized APEP could deliver important outcomes to improve economic resilience, supply chains, lower costs, harness the digital economy, and improve environmental and labour standards. In particular, APEP could open up new avenues of economic, social, labour, environmental, and good governance cooperation. It is an opportunity to advance existing Canadian trade policy priorities, and economic cooperation in the region, while supporting Canadian foreign policy priorities and contributing to other commitments such as the L.A. Declaration on Migration and Canada’s Feminist International Assistance Policy objectives in the region.

Submissions guidelines

To assist the Government of Canada in APEP negotiations, Global Affairs Canada welcomes submissions from interested stakeholders, provinces and territories, and Indigenous Peoples. Individuals, groups and organizations are invited to consider and comment on the opportunities and effects that could arise from Canada’s participation in the APEP.

The U.S. White House Fact Sheet of the initiative outlines the anticipated scope of the four pillars (detailed below) and the types of issues that participants have agreed to consider. The submission of additional ideas about what could be contained in a regional economic framework, focused on current and future opportunities and challenges, is encouraged.

More information on the Government’s consultations on possible future APEP negotiations can be found on the Global Affairs Canada website.

Interested parties are invited to submit their views by May 9, 2023, to help shape the approach to upcoming negotiations. Officials will remain open for further submissions after this time and throughout negotiations. Submissions received by Global Affairs Canada become records under its control. In the event of a request under the Access to Information Act, relevant records are released subject to applicable exceptions to disclosure under the Act. Please read the privacy notice carefully prior to sending a written submission.

Submissions should include the following information:

  1. the contributor’s name and address and, if applicable, the name of the contributor’s organization, institution or business;
  2. the specific issues being addressed; and
  3. where possible, precise information on the rationale for the positions taken, including any significant impact it may have on Canada’s domestic or international interests.

Contributions can be sent to

Americas Partnership for Economic Prosperity (APEP) Consultations

Global Affairs Canada
Trade Negotiations — North America (TNP), Americas Branch (NDS)

John G. Diefenbaker Building
111 Sussex Drive
Ottawa, Ontario
K1N 1J1
Email: APEP-Consultations-PAPE@international.gc.ca

Submissions by interested parties

The Government would appreciate receiving views from Canadians on the scope of the initiative as outlined in the Fact Sheet published by the United States on January 27, 2023.

Other topics of interest to Canadians

The Government would welcome any other views on the following topics that could be relevant to APEP negotiations and engagement with APEP partners:

PRIVY COUNCIL OFFICE

Appointment opportunities

We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.

We are equally committed to providing a healthy workplace that supports one’s dignity, self-esteem and the ability to work to one’s full potential. With this in mind, all appointees will be expected to take steps to promote and maintain a healthy, respectful and harassment-free work environment.

The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council appointments website.

Governor in Council appointment opportunities
Position Organization Closing date
Director Asia-Pacific Foundation of Canada  
Director Atomic Energy of Canada Limited  
Director Bank of Canada  
Chairperson Business Development Bank of Canada  
Director Business Development Bank of Canada  
Director Canada Council for the Arts  
Director Canada Deposit Insurance Corporation  
Director Canada Foundation for Sustainable Development Technology  
President Canada Lands Company Limited  
Director Canada Post Corporation  
Director Canada Revenue Agency  
Chairperson Canadian Air Transport Security Authority  
Chief Executive Officer Canadian Air Transport Security Authority  
Director Canadian Commercial Corporation  
Member Canadian Cultural Property Export Review Board  
Director Canadian Energy Regulator  
Chief Commissioner Canadian Human Rights Commission  
Pay Equity Commissioner Canadian Human Rights Commission  
Member Canadian Human Rights Tribunal  
Member Canadian Institutes of Health Research  
President Canadian Institutes of Health Research  
Member Canadian International Trade Tribunal  
Secretary Canadian Intergovernmental Conference Secretariat  
Trustee Canadian Museum of Immigration at Pier 21  
Permanent Member Canadian Nuclear Safety Commission  
President Canadian Nuclear Safety Commission  
Member Canadian Radio-television and Telecommunications Commission  
Member Canadian Statistics Advisory Council  
Member Canadian Transportation Accident Investigation and Safety Board  
Member Canadian Transportation Agency  
Chairperson Export Development Canada  
Director Export Development Canada  
Director First Nations Financial Management Board  
Commissioner First Nations Tax Commission  
Deputy Administrator Fund for Railway Accidents Involving Designated Goods  
Member Historic Sites and Monuments Board of Canada  
Commissioner International Commission on the Conservation of Atlantic Tunas  
President International Development Research Centre  
Commissioner International Joint Commission  
Chairperson Military Grievances External Review Committee  
Vice-Chairperson Military Grievances External Review Committee  
Commissioner National Battlefields Commission  
Chairperson National Capital Commission  
Member National Capital Commission  
Member National Farm Products Council  
Vice-Chairperson National Farm Products Council  
Director National Gallery of Canada  
Member Net-Zero Advisory Body  
Canadian Representative North Atlantic Salmon Conservation Organization  
Canadian Representative North Pacific Anadromous Fish Commission  
Public Sector Integrity Commissioner Office of the Public Sector Integrity Commissioner  
Member Pacific Pilotage Authority  
Member Patented Medicine Prices Review Board  
Vice-Chairperson Patented Medicine Prices Review Board  
Commissioner Public Service Commission  
Member Royal Canadian Mounted Police Management Advisory Board  
Principal Royal Military College of Canada  
Deputy Administrator Ship-source Oil Pollution Fund  
Member Standards Council of Canada  
Chief Executive Officer VIA Rail Canada Inc.  
Chief Executive Officer Windsor-Detroit Bridge Authority